Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.63 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.63 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 8/20 | 0.56 |
| ▸ | KCNK9 | Q9NPC2 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13234 | 0.87 | GABRA2 (0.63) | GABRA2GABRB2SLC2A2KCNK3KCNK9 | |
| SCHEMBL30417903 | 0.84 | KCNK3 (0.58) | GABRA2GABRB2SLC2A2KCNK3KCNK9 | |
| SCHEMBL18963146 | 0.82 | KDM4E (0.78) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| Hydrochloric Acid SCHEMBL18952318 | 0.81 | KDM4E (0.77) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL8208 | 0.80 | KDM4E (0.64) | GABRB2SLC2A2KCNK3KCNK9KDM4E | |
| SCHEMBL30417684 | 0.79 | KCNK3 (0.49) | SLC2A2KCNK3KCNK9KDM4EGAA | |
| SCHEMBL30417709 | 0.78 | KCNK3 (0.49) | SLC2A2KCNK3KCNK9KDM4EGAA | |
| SCHEMBL30417727 | 0.77 | KCNK3 (0.68) | KCNK3KCNK9 | |
| SCHEMBL30417581 | 0.77 | KCNK3 (0.61) | KCNK3KCNK9 | |
| SCHEMBL7231287 | 0.76 | KCNK3 (0.65) | KCNK3KCNK9KDM4EGAASLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4452264-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452263-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A P2X3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023118126-A1 | COMBINATION OF A TASK1/3 CHANNEL BLOCKER WITH A NOREPINEPHRINE REUPTAKE INHIBITOR FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | WO | disclosed |